Company Profile
Shenzhen Hepalink Pharmaceutical provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and globally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs
Molecule biologics CDMO services, which include R&D, manufacturing, quality management, and program management services, as well as technical support services. Additionally, it develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events in Phase 2 trial for diabetic nephropathy and fatty disease.
Its portfolio also includes oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer in Phase 2 for pancreatic cancer, tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia, and H1710, a heparanase inhibitor preparation for solid tumors
Property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities. Its portfolio also includes provision of services on pharmaceutical related activities, and trading of medical and biopharmaceutical products. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. Founded in 1998, the company is headquartered in Shenzhen, the People's Republic of China.